ALLERGAN AUSTRALIA PTY LIMITED

Incyte has appointed Bill Meury as its new CEO, effective immediately, replacing Hervé Hoppenot who led the cancer and blood disease drugmaker for 11 years.

Amneal Pharmaceuticals received FDA approval for prednisolone acetate ophthalmic suspension 1%, a generic version of Allergan's Pred Forte for treating steroid-responsive ocular inflammation.

CollPlant Biotechnologies has expanded its collaboration with STEMCELL Technologies to include clinical development and commercial-scale manufacturing of its plant-derived recombinant human collagen (rhCollagen).

CollPlant reported encouraging preclinical results for its regenerative breast implants, which demonstrated vascularization, tissue ingrowth, and biodegradation while maintaining structural integrity six months post-implantation.

A phase 4 multicenter study demonstrated that perfluorohexyloctane (MIEBO) provides significant dry eye symptom relief within just 5 minutes of application, showing nearly 50% improvement that continued to increase at subsequent timepoints.

Paul Stoffels will retire as Galapagos CEO within 12 months after three years at the helm, during which he transformed the company's focus to cell therapy and oncology through strategic acquisitions.

• SpyGlass Pharma has appointed Chetan Pujara, Ph.D., as Chief Research & Development Officer to lead the company's proprietary intraocular drug delivery platform into Phase 3 trials. • Dr. Pujara brings over 20 years of leadership experience in pharmaceutical development and has contributed to market-leading products including Ozurdex®, Durysta™, and other ophthalmic therapies. • The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver three years of sustained medication release for glaucoma patients, with potential applications in additional ophthalmic conditions.

• The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions. • Several pharmaceutical companies including NeuroRx, COMPASS Pathways, and Intra-Cellular Therapies are advancing novel treatments, with Johnson & Johnson's recent $14.6 billion acquisition of Intra-Cellular Therapies highlighting industry confidence in the sector. • Among current therapies, CAPLYTA (lumateperone) is expected to achieve the highest market share by 2034, while emerging treatments like NRX-100/101 and COMP 360 (psilocybin) show promise for addressing unmet needs in bipolar depression management.

New research from University of Bath and Lund University exposes significant transparency issues in the UK's voluntary pharmaceutical payment disclosure system, with £3.3 billion in research payments lacking recipient details.

Analysis of US ophthalmic clinical trials reveals key enrollment trends, aiding researchers in planning and resource allocation.